Anesthetic Management in Patients Undergoing Epicardial Ablation

Completed

• Conditions: Ventricular Tachycardia

• Registration Number: NCT06538987
• Lead Sponsor: Eskisehir Osmangazi University

Brief Summary

The study is a retrospective study and is descriptive in nature. In this study, the investigators aimed to emphasize the importance of anesthesia management by cardiac risk assessment of patients undergoing epicardial ablation under general anesthesia and analysis of complications that developed during the procedure.

Detailed Description

The study is retrospective observational and data were collected by examining the files of all epicardial ablation patients received in the angiography unit starting from 30.10.2020 until 30.10.2022 after ethics committee approval is obtained. Baseline characteristic features of the patients Sex, Age, (years, BMI (kg/m2) Hypertension, Coronary artery disease, COPD (Chronic obstructive pulmonary disease), CKD (Chronic kidney disease) Electrical storm, and ventricular tachycardia etiology, Ischemic cardiomyopathy, Dilated cardiomyopathy, the presence of ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy), Hypertrophic cardiomyopathy will be recorded. NHYA classification will be examined in two groups as NHYA I or II and NHYA III or IV, also estimated glomerular filtration rate, left ventricular ejection fraction, PAAINESD (acute hemodynamic decompensation risk assessment score), iVT score (Risk of VT recurrence) Score information will be recorded. Ventricular tachycardia focus locations, dopamine, dobutamine, norepinephrine infusion requirement during the procedure, arrest development during the procedure, fluoroscopy time and ablation times will be recorded. In the follow-up of the patients after the procedure Causes of death, decompensated heart failure, transient ischemic attack, development of acute renal failure, and recurrence of ventricular tachycardia will be recorded. PAAINESD score (acute hemodynamic decompensation risk assessment score) will be recorded. The PAAINESD Score, developed to estimate the risk of periprocedural hemodynamic decompensation, has values ranging from 0 to 35 points (or 0 to 31 \[PAINESD\] when the modifiable intraprocedural variable "general anesthesia" is excluded). duration of the procedure, the need for inotropes during the procedure, whether the patient needed mechanical ventilation after the procedure, and the success rates after the procedure will be recorded.

PAINESD Pulmonary disease (chronic obstructive pulmonary disease) 5 Age \>60 years 3 Anaesthesia (general) 4 Ischaemic cardiomyopathy 6 NYHA class III or IV 6 Ejection fraction \<25 % 3 Storm (VT). 5 Diabetes 3 Data will be analyzed in three separate categories, the characteristics of the patients before the procedure, during the procedure and after the procedure. Descriptive tables and percentages of parameters will be created by statistical analysis.

Study Timeline

• Study First Submitted: 2024-07-08
• Study First Submitted QC: 2024-08-02
• Study First Posted: 2024-08-06
• Study Start: 2024-08-30
• Primary Completion: 2024-09-30
• Study Completion: 2024-10-30
• Status Verified: 2025-03
• Last Update Submitted: 2025-05-01
• Last Update Posted: 2025-05-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• age > 18 years old who underwent elective VT ablation between 2020 - 2022,

• primary anesthetic type listed as general anesthesia

Exclusion Criteria

• age < 18 years,

• missing follow-up data,
• patients who have previously undergone epicardial ablation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
sex	2 years	male %
age	2 years	years
weight	2 years	kilograms
height	2 years	meters
Hypertension	2 years	yes or no
Diabetes mellitus	2 years	yes or no
Coronary artery disease	2 years	yes or no
Chronic obstructive pulmonary disease	2 years	yes or no
Chronic kidney disease	2 years	yes or no
Systolic pulmonary artery pressure	2 years	mmHg
Left ventricular ejection	2 years	%
PAAINESD (Acute hemodynamic decompensation risk assessment, ranging from 0 to 35 points, 35 point is the worst) score	2 years	score 0-35
ASA ( American Society of Anesthesiologists (ASA) physical status classification ranging from I to IV	2 years	score I-IV
Hemoglobin	2 years	g/dl
glomerular filtration rate (eGFR)	2 years	ml/dak/1,73m2
Total procedural time	2 years	minutes
Fluoroscopy time	2 years	minutes
Ablation time	2 years	minutes

Secondary Outcome Measures

Name	Time	Method
Transient ischemic attack after procedure	2 years	yes or no
Exitus during the follow-up	2 years	yes or no
cause of death	2 years	End-Stage heart failure, VT storm

Trial Locations

Locations (1)

University of Eskisehir Osmangazi; 🇹🇷 Eski̇şehi̇r, Odunpazarı, Turkey